50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today CLLS ranks #10865 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cellectis S.A. Stock Forecast NASDAQ:CLLS

$8.69 (-0.34%)

Volume: 82k

Closed: Nov 26, 2021

Hollow Logo Score: -3.441

Cellectis S.A. Stock Forecast

$8.69 (-0.34%)

Volume: 82k

Closed: Nov 26, 2021

Score Hollow Logo -3.441
Which way will CLLS go? Request
Key Stats
Beta 2.09
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 13 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Cellectis S.A. stock upgraded to Sell Candidate.
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-08 Loss -25.54%

The Cellectis S.A. stock price fell by -0.34% on the last day (Friday, 26th Nov 2021) from $8.72 to $8.69. During the day the stock fluctuated 2.99% from a day low at $8.53 to a day high of $8.79. The price has fallen in 8 of the last 10 days and is down by -15.96% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -33 thousand shares and in total, 82 thousand shares were bought and sold for approximately $710.09 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -33.61% during the next 3 months and, with a 90% probability hold a price between $3.99 and $7.55 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, November 23, 2021, and so far it has risen 4.20%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Cellectis S.A. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $8.79 and $10.41. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

Cellectis S.A. finds support from accumulated volume at $8.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved $0.26 between high and low, or 2.99%. For the last week the stock has had a daily average volatility of 4.47%.

Cellectis S.A. is oversold on RSI14 (13). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Cellectis S.A. stock A Buy?

Cellectis S.A. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

Current score: -3.441

Predicted Opening Price for Cellectis S.A. of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$8.67 $8.69 (Overvalued)
Sell Candidate Upgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 08, 2021 "William Blair" gave "" rating for CLLS. The price target was changed from $11.35 to 7.2%.

Volatility and Risk
Daily Average Volatility: 4.47 %
Overall Risk: Very High High Medium Low Very Low
4.47 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $9.11
Price: $8.69
Support: $8.36

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 8.92 2.69 %
8.83 1.56 %
8.77 0.87 %
Current price: 8.69
Support 8.57 -1.37 %
8.51 -2.06 %
8.41 -3.18 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 10.70 23.13 %
9.62 10.70 %
9.11 4.83 %
Current price 8.69
Support 8.36 -3.80%
8.34 -4.03%
0 .

Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis SA Cellectis S.A., a gene-editing company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. The company’s products also include UCART1... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE